ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS

Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA ) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices. The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose that: ADMA Biologics engaged in an undisclosed related party transaction; ADMA Biologics used channel stuffing to create an appearance of revenue; ADMA Biologics lacked adequate internal controls; and As a result, Defendants' statements about ADMA Biologics' business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The suit alleges that the misstatements were revealed through several corrective disclosure events, which wiped out substantial shareholder value, exposing investors to severe financial harm. Date Corrective Event Stock Price Impact March 24, 2026 Culper Research publishes short-seller report revealing channel stuffing, rebates, and undisclosed related-party distributor Genesis BioPharma, triggering intense market sell-offs over two trading days as investors digest the revelations. -31.6% combined (March 24: Down 16.6% to $11.33) (March 25: Down 15.0% to $9.63) March 26, 2026 ADMA issues a press release responding to the short-seller report stating it was "taking appropriate steps to review the assertions," alongside a stock rating downgrade from Cantor Fitzgerald, further eroding investor confidence. -13.9% (Down $1.34 to close at $8.29) "We're investigation whether ADMA made false and misleading statements to investors concealing the reality of its distribution channels and financial reporting, as the suit alleges " said Reed Kathrein , the Hagens Berman partner leading the firm's investigation of the lawsuit's claims.